Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
NCT05657990Phase 1Recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Apr 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tamsulosin in postoperative urinary retention (POUR), sponsored by Hackensack Meridian Health. Primary endpoints: Number of participants that were able to spontaneously void after surgery completion, Time of the void at 24 hours and 3 more. Started Apr 2023; status: recruiting.
02
Drugs
tamsulosin
03
Conditions
postoperative urinary retention (POUR)
Beyond the preview
Go deeper on NCT05657990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657990.